Trial Profile
A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ladostigil (Primary)
- Indications Mild cognitive impairment
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Avraham Pharmaceuticals
- 06 Sep 2019 Results assessing safety of ladostigil in patients with in patients with mild cognitive impairment, published in the Neurology.
- 14 Jun 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2016 This trial was completed in Germany (end date: 26-07-2016), according to European Clinical Trials Database.